Takeda's 2016 underlying revenue up 6.9%, core earnings up 24.2% — 9 things to know

Takeda Pharmaceuticals reported underlying revenue growth of 6.9 percent from fiscal year 2015 to fiscal year 2016.

Here's what you should know.

1. Takeda's gastroenterology, oncology and emerging market platforms increased growth by 14.7 percent. Underlying revenue grew across all regions with the U.S. increasing 12.8 percent.

2. Takeda's reported revenues fell 4.2 percent from $1.8 billion to $1.7 billion. Takeda attributed the decrease to unfavorable currencies and divestitures' negative impact.

3. Underlying core earnings grew 24.2 percent. Reported operating profit was up 10.1 percent.

4. Reported core earnings were down 16 percent from $292 million to $245.1 million.

5. Operating profit increased 19.1 percent from $130.8 million to $155.9 million.

2017 forecast
6. Takeda expects revenue to drop 3 percent from $1.73 billion to $1.68 billion.

7. Takeda expects operating profits to rise 15.5 percent from $155.9 million to $180 million.

8. The forecast expects net profits will increase 20.1 percent from $114.9 million to $138 million.

9. Takeda expects earnings per share of $1.54 for fiscal year 2017.

More articles on gastroenterology:
Autonomously capsule robot could improve colonoscopy acceptance, accuracy
6 GI companies making waves: Olympus, Pfizer & more
GI leader to know: Dr. Masi Khaja of Gastroenterology Associates of Western Colorado

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months